Lipidor Ab (LIPI) - Total Assets
Based on the latest financial reports, Lipidor Ab (LIPI) holds total assets worth Skr11.58 Million SEK (≈ $1.25 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lipidor Ab - Total Assets Trend (2016–2024)
This chart illustrates how Lipidor Ab's total assets have evolved over time, based on quarterly financial data. Also see LIPI company net worth for the company's overall valuation and market capitalisation.
Lipidor Ab - Asset Composition Analysis
Current Asset Composition (December 2024)
Lipidor Ab's total assets of Skr11.58 Million consist of 97.3% current assets and 2.7% non-current assets. Review LIPI current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 88.2% |
| Accounts Receivable | Skr386.00K | 3.3% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Lipidor Ab's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See LIPI share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lipidor Ab's current assets represent 97.3% of total assets in 2024, an increase from 7.4% in 2016.
- Cash Position: Cash and equivalents constituted 88.2% of total assets in 2024, up from 2.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 88.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 3.3% of total assets.
Lipidor Ab Competitors by Total Assets
Key competitors of Lipidor Ab based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $136.46 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
MX:AZNN
|
Mexico | MX$114.07 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $122.03 Billion |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357
|
China | CN¥2.89 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
Lipidor Ab - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.92 | 0.12 | 18.83 |
| Quick Ratio | 2.92 | 0.12 | 18.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr7.41 Million | Skr-10.65 Million | Skr26.25 Million |
Lipidor Ab - Advanced Valuation Insights
This section examines the relationship between Lipidor Ab's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.65 |
| Latest Market Cap to Assets Ratio | 1.63 |
| Asset Growth Rate (YoY) | 310.1% |
| Total Assets | Skr11.58 Million |
| Market Capitalization | $18.82 Million USD |
Valuation Analysis
Above Book Valuation: The market values Lipidor Ab's assets above their book value (1.63x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Lipidor Ab's assets grew by 310.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Lipidor Ab (2016–2024)
The table below shows the annual total assets of Lipidor Ab from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr11.58 Million ≈ $1.25 Million |
+310.09% |
| 2023-12-31 | Skr2.82 Million ≈ $303.91K |
-81.92% |
| 2022-12-31 | Skr15.62 Million ≈ $1.68 Million |
-71.61% |
| 2021-12-31 | Skr55.02 Million ≈ $5.92 Million |
-16.48% |
| 2020-12-31 | Skr65.88 Million ≈ $7.09 Million |
+132.80% |
| 2019-12-31 | Skr28.30 Million ≈ $3.05 Million |
+55.61% |
| 2018-12-31 | Skr18.18 Million ≈ $1.96 Million |
+297.23% |
| 2017-12-31 | Skr4.58 Million ≈ $492.67K |
+81.63% |
| 2016-12-31 | Skr2.52 Million ≈ $271.25K |
-- |
About Lipidor Ab
Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermat… Read more